SYRS
Syros Pharmaceuticals, Inc.
Biotechnology
Market Cap$11K
5Y Perf.-100.0%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
SYRS vs IMVT
Revenue, margins, valuation, and 5-year total return — side by side.
IMVT
Immunovant, Inc.
Biotechnology
Market Cap$5.53B
5Y Perf.+5.8%
SYRS vs IMVT — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | SYRS | IMVT |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $11K | $5.53B |
| Revenue (TTM) | $386K | $0.00 |
| Net Income (TTM) | $-98M | $-464M |
| Gross Margin | -228.8% | — |
| Operating Margin | -288.9% | — |
| Total Debt | $62M | $98K |
| Cash & Equiv. | $140M | $714M |
SYRS vs IMVT — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
SYRS
IMVT
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Syros Pharmaceutica… (SYRS) | 100 | 0.0 | -100.0% |
| Immunovant, Inc. (IMVT) | 100 | 105.8 | +5.8% |
Price return only. Dividends and distributions are not included.
Quick Verdict: SYRS vs IMVT
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: IMVT leads in 4 of 6 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. Syros Pharmaceuticals, Inc. is the stronger pick specifically for capital preservation and lower volatility. As sector peers, any of these can serve as alternatives in the same allocation.
SYRS
Syros Pharmaceuticals, Inc.
The Income Pick
SYRS is the clearest fit if your priority is income & stability and growth exposure.
- beta 1.37
- Rev growth -33.2%, EPS growth 22.4%, 3Y rev CAGR -13.0%
- Lower volatility, beta 1.37, current ratio 3.95x
Best for: income & stability and growth exposure
IMVT
Immunovant, Inc.
The Long-Run Compounder
IMVT carries the broadest edge in this set and is the clearest fit for long-term compounding.
- 173.6% 10Y total return vs SYRS's -100.0%
- -21.3% revenue growth vs SYRS's -33.2%
- 3.2% margin vs SYRS's -253.4%
Best for: long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | IMVT | -21.3% revenue growth vs SYRS's -33.2% |
| Quality / Margins | IMVT | 3.2% margin vs SYRS's -253.4% |
| Stability / Safety | SYRS | Beta 1.37 vs IMVT's 1.37 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | IMVT | +96.1% vs SYRS's -99.0% |
| Efficiency (ROA) | IMVT | -44.1% ROA vs SYRS's -115.1% |
SYRS vs IMVT — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLIMVTLAGGINGSYRS
SYRSSyros Pharmaceuticals…
1leads
IMVTImmunovant, Inc.
2leads
6 Total Categories
CATEGORYLEADERvs SYRSMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
SYRS1/1
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
IMVT7/7
Total Returns1Y, 3Y, 5Y total returns with dividends
IMVT5/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
SYRS leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
SYRS and IMVT operate at a comparable scale, with $386,000 and $0 in trailing revenue.
| Metric | SYRSSyros Pharmaceuti… | IMVTImmunovant, Inc. |
|---|---|---|
| RevenueTrailing 12 months | $386,000 | $0 |
| EBITDAEarnings before interest/tax | -$110M | -$487M |
| Net IncomeAfter-tax profit | -$98M | -$464M |
| Free Cash FlowCash after capex | -$100M | -$423M |
| Gross MarginGross profit ÷ Revenue | -2.3% | — |
| Operating MarginEBIT ÷ Revenue | -288.9% | — |
| Net MarginNet income ÷ Revenue | -253.4% | — |
| FCF MarginFCF ÷ Revenue | -259.2% | — |
| Rev. Growth (YoY)Latest quarter vs prior year | -100.0% | — |
| EPS Growth (YoY)Latest quarter vs prior year | +88.8% | +19.7% |
SYRS leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
Evenly matched — SYRS and IMVT each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | SYRSSyros Pharmaceuti… | IMVTImmunovant, Inc. |
|---|---|---|
| Market CapShares × price | $10,733 | $5.5B |
| Enterprise ValueMkt cap + debt − cash | -$77M | $4.8B |
| Trailing P/EPrice ÷ TTM EPS | -0.00x | -9.97x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 0.00x | — |
| Price / BookPrice ÷ Book value/share | 0.00x | 5.83x |
| Price / FCFMarket cap ÷ FCF | — | — |
Evenly matched — SYRS and IMVT each lead in 1 of 2 comparable metrics.
Profitability & Efficiency
IMVT leads this category, winning 7 of 7 comparable metrics.
Profitability & Efficiency
IMVT delivers a -47.1% return on equity — every $100 of shareholder capital generates $-47 in annual profit, vs $-2 for SYRS. IMVT carries lower financial leverage with a 0.00x debt-to-equity ratio, signaling a more conservative balance sheet compared to SYRS's 3.73x. On the Piotroski fundamental quality scale (0–9), IMVT scores 2/9 vs SYRS's 1/9, reflecting mixed financial health.
| Metric | SYRSSyros Pharmaceuti… | IMVTImmunovant, Inc. |
|---|---|---|
| ROE (TTM)Return on equity | -2.3% | -47.1% |
| ROA (TTM)Return on assets | -115.1% | -44.1% |
| ROICReturn on invested capital | — | — |
| ROCEReturn on capital employed | -74.7% | -66.1% |
| Piotroski ScoreFundamental quality 0–9 | 1 | 2 |
| Debt / EquityFinancial leverage | 3.73x | 0.00x |
| Net DebtTotal debt minus cash | -$77M | -$714M |
| Cash & Equiv.Liquid assets | $140M | $714M |
| Total DebtShort + long-term debt | $62M | $98,000 |
| Interest CoverageEBIT ÷ Interest expense | -17.35x | — |
IMVT leads this category, winning 7 of 7 comparable metrics.
Total Returns (Dividends Reinvested)
IMVT leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in IMVT five years ago would be worth $16,241 today (with dividends reinvested), compared to $0 for SYRS. Over the past 12 months, IMVT leads with a +96.1% total return vs SYRS's -99.0%. The 3-year compound annual growth rate (CAGR) favors IMVT at 12.1% vs SYRS's -94.9% — a key indicator of consistent wealth creation.
| Metric | SYRSSyros Pharmaceuti… | IMVTImmunovant, Inc. |
|---|---|---|
| YTD ReturnYear-to-date | +100.0% | +5.1% |
| 1-Year ReturnPast 12 months | -99.0% | +96.1% |
| 3-Year ReturnCumulative with dividends | -100.0% | +40.9% |
| 5-Year ReturnCumulative with dividends | -100.0% | +62.4% |
| 10-Year ReturnCumulative with dividends | -100.0% | +173.6% |
| CAGR (3Y)Annualised 3-year return | -94.9% | +12.1% |
IMVT leads this category, winning 5 of 6 comparable metrics.
Risk & Volatility
Evenly matched — SYRS and IMVT each lead in 1 of 2 comparable metrics.
Risk & Volatility
SYRS is the less volatile stock with a 1.37 beta — it tends to amplify market swings less than IMVT's 1.37 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. IMVT currently trades 90.5% from its 52-week high vs SYRS's 0.9% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | SYRSSyros Pharmaceuti… | IMVTImmunovant, Inc. |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.37x | 1.37x |
| 52-Week HighHighest price in past year | $0.04 | $30.09 |
| 52-Week LowLowest price in past year | $0.00 | $13.36 |
| % of 52W HighCurrent price vs 52-week peak | +0.9% | +90.5% |
| RSI (14)Momentum oscillator 0–100 | 47.9 | 60.2 |
| Avg Volume (50D)Average daily shares traded | 5K | 1.4M |
Evenly matched — SYRS and IMVT each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
| Metric | SYRSSyros Pharmaceuti… | IMVTImmunovant, Inc. |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy |
| Price TargetConsensus 12-month target | — | $45.50 |
| # AnalystsCovering analysts | — | 23 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
IMVT leads in 2 of 6 categories (Profitability & Efficiency, Total Returns). SYRS leads in 1 (Income & Cash Flow). 2 tied.
Best OverallImmunovant, Inc. (IMVT)Leads 2 of 6 categories
Loading custom metrics...
SYRS vs IMVT: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is SYRS or IMVT a better buy right now?
Analysts rate Immunovant, Inc.
(IMVT) a "Buy" — based on 23 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — SYRS or IMVT?
Over the past 5 years, Immunovant, Inc.
(IMVT) delivered a total return of +62. 4%, compared to -100. 0% for Syros Pharmaceuticals, Inc. (SYRS). Over 10 years, the gap is even starker: IMVT returned +173. 6% versus SYRS's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — SYRS or IMVT?
By beta (market sensitivity over 5 years), Syros Pharmaceuticals, Inc.
(SYRS) is the lower-risk stock at 1. 37β versus Immunovant, Inc. 's 1. 37β — meaning IMVT is approximately 1% more volatile than SYRS relative to the S&P 500. On balance sheet safety, Immunovant, Inc. (IMVT) carries a lower debt/equity ratio of 0% versus 4% for Syros Pharmaceuticals, Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — SYRS or IMVT?
On earnings-per-share growth, the picture is similar: Syros Pharmaceuticals, Inc.
grew EPS 22. 4% year-over-year, compared to -45. 2% for Immunovant, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — SYRS or IMVT?
Immunovant, Inc.
(IMVT) is the more profitable company, earning 0. 0% net margin versus -1656. 3% for Syros Pharmaceuticals, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: IMVT leads at 0. 0% versus -1298. 2% for SYRS. At the gross margin level — before operating expenses — SYRS leads at 77. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — SYRS or IMVT?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is SYRS or IMVT better for a retirement portfolio?
For long-horizon retirement investors, Immunovant, Inc.
(IMVT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (+173. 6% 10Y return). Both have compounded well over 10 years (IMVT: +173. 6%, SYRS: -100. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between SYRS and IMVT?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.